A Phase 2 interventional study of BMS-986165 and Placebo in Granulomatous Colitis, Crohn's Disease and Crohn's Enteritis, sponsored by Bristol-Myers Squibb. Terminated at 259 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Crohn Disease by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Crohn Disease · Bristol-Myers Squibb.
Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, this one is the 8th largest by enrollment, is one of 5 that started in 2018, is one of 6 in phase 2, and was the 14th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 16 studies in Crohn Disease by Bristol-Myers Squibb is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 9
First in 2002; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 239 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 180 across the 16 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986165
Drug: BMS-986165
Other: Placebo
Specified dose on specified days
Specified dose on specified days
Percent of Participants Achieving Clinical Remission at Week 12
Percent of participants achieving clinical remission at Week 12. Clinical remission is defined as achieving a Crohn's Disease Activity Index (CDAI) Score below 150. CDAI is a tool that helps doctors measure how severe someone's Crohn's disease is. It uses questions about symptoms experienced over a week to calculate a score. The scores range from 0 to 600 and are classified into different categories. Scores from 0 to 149 suggest the disease may be in remission. Scores from 150 to 220 indicate mild activity. Scores from 220 to 450 mean the disease is moderate to severe. Scores from 451 to 600 indicate severe disease. Higher scores mean more severe symptoms. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.
Time frame: 12 weeks after first dose
Percent of Participants Achieving Endoscopic Response at Week 12
Endoscopic Response is defined as \>= 50% decrease from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel and checks for things like ulcers and inflammation. Each part is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease. Baseline refers to the initial set of before data collected from participants before starting study treatment. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.
Time frame: 12 weeks after first dose
Percent of Participants Achieving Clinical Response at Week 12
Clinical response is defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of ≥ 100 points or a total CDAI score \< 150. CDAI is a tool that helps doctors measure how severe someone's Crohn's disease is. It uses questions about symptoms experienced over a week to calculate a score. The scores range from 0 to 600 and are classified into different categories. Scores from 0 to 149 suggest the disease may be in remission. Scores from 150 to 220 indicate mild activity. Scores from 220 to 450 mean the disease is moderate to severe. Scores from 451 to 600 indicate severe disease. Higher scores mean more severe symptoms. Baseline refers to the initial set of before data collected from participants before starting study treatment. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.
Time frame: 12 weeks after first dose
Percent of Participants Who Achieving Patient Reported Outcomes 2 (PRO2) Remission at Week 12
The Patient Reported Outcomes 2 (PRO2) is a way for patients to report how they're feeling. It focuses on two things: how often they have loose or liquid stools, and how much abdominal pain they have. They keep track of these things every day for a week. Stool frequency is rated on a scale from 0 to 3, with 0 being the normal number of stools per day to 3 which is \>/=5 stools more than normal per day. The pain is rated on a scale from 0 to 3, with 0 being no pain and 3 being severe pain. The scores for these two things are added up to get a total score ranging from 0-6. If the average daily score for abdominal pain is 1 or less, and the average number of loose or liquid stools is 3 or less, then the disease might be in remission. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.
Time frame: 12 weeks after first dose
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12
The SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel and checks for ulcer size, ulcerated surface, inflamed surface, and stenosis. Each is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease. Baseline refers to the initial set of before data collected from participants starting study treatment.
Time frame: 12 weeks after first dose
This study has a treat-through design
| Milestone | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 |
|---|---|---|---|---|
| Started | 60 | 86 | 84 | 9 |
| Completed | 59 | 84 | 83 | 9 |
| Not completed | 1 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Other reasons | 1 | 1 | 1 | 0 |
| Milestone | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 |
|---|---|---|---|---|
| Started | 59 | 84 | 83 | 9 |
| Completed | 13 | 14 | 14 | 4 |
| Not completed | 46 | 70 | 69 | 5 |
| Withdrew: Adverse event | 11 | 20 | 18 | 2 |
| Withdrew: Lack of efficacy | 18 | 12 | 13 | 2 |
| Withdrew: Withdrawal by subject | 5 | 11 | 16 | 1 |
| Withdrew: Other reasons | 4 | 6 | 7 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 7 | 20 | 15 | 0 |
| Withdrew: Site terminated by sponsor | 0 | 1 | 0 | 0 |
Percent of participants achieving clinical remission at Week 12. Clinical remission is defined as achieving a Crohn's Disease Activity Index (CDAI) Score below 150. CDAI is a tool that helps doctors measure how severe someone's Crohn's disease is. It uses questions about symptoms experienced over a week to calculate a score. The scores range from 0 to 600 and are classified into different categories. Scores from 0 to 149 suggest the disease may be in remission. Scores from 150 to 220 indicate mild activity. Scores from 220 to 450 mean the disease is moderate to severe. Scores from 451 to 600 indicate severe disease. Higher scores mean more severe symptoms. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.
| Percent of Participants | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 |
|---|---|---|---|---|
| Percent of Participants Achieving Clinical Remission at Week 12 | 28.3 (16.9 to 39.7) | 32.6 (22.7 to 42.5) | 21.4 (12.7 to 30.2) | 22.2 (0.0 to 49.4) |
Endoscopic Response is defined as \>= 50% decrease from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel and checks for things like ulcers and inflammation. Each part is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease. Baseline refers to the initial set of before data collected from participants before starting study treatment. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.
| Percent of Participants | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 |
|---|---|---|---|---|
| Percent of Participants Achieving Endoscopic Response at Week 12 | 8.3 (1.3 to 15.3) | 23.3 (14.3 to 32.2) | 16.7 (8.7 to 24.6) | 33.3 (2.5 to 64.1) |
Clinical response is defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of ≥ 100 points or a total CDAI score \< 150. CDAI is a tool that helps doctors measure how severe someone's Crohn's disease is. It uses questions about symptoms experienced over a week to calculate a score. The scores range from 0 to 600 and are classified into different categories. Scores from 0 to 149 suggest the disease may be in remission. Scores from 150 to 220 indicate mild activity. Scores from 220 to 450 mean the disease is moderate to severe. Scores from 451 to 600 indicate severe disease. Higher scores mean more severe symptoms. Baseline refers to the initial set of before data collected from participants before starting study treatment. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.
| Percent of Participants | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 |
|---|---|---|---|---|
| Percent of Participants Achieving Clinical Response at Week 12 | 40.0 (27.6 to 52.4) | 47.7 (37.1 to 58.2) | 38.1 (27.7 to 48.5) | 55.6 (23.1 to 88.0) |
The Patient Reported Outcomes 2 (PRO2) is a way for patients to report how they're feeling. It focuses on two things: how often they have loose or liquid stools, and how much abdominal pain they have. They keep track of these things every day for a week. Stool frequency is rated on a scale from 0 to 3, with 0 being the normal number of stools per day to 3 which is \>/=5 stools more than normal per day. The pain is rated on a scale from 0 to 3, with 0 being no pain and 3 being severe pain. The scores for these two things are added up to get a total score ranging from 0-6. If the average daily score for abdominal pain is 1 or less, and the average number of loose or liquid stools is 3 or less, then the disease might be in remission. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.
| Percent of Participants | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 |
|---|---|---|---|---|
| Percent of Participants Who Achieving Patient Reported Outcomes 2 (PRO2) Remission at Week 12 | 25.0 (14.0 to 36.0) | 32.6 (22.7 to 42.5) | 20.2 (11.6 to 28.8) | 33.3 (2.5 to 64.1) |
The SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel and checks for ulcer size, ulcerated surface, inflamed surface, and stenosis. Each is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease. Baseline refers to the initial set of before data collected from participants starting study treatment.
| Change in Score on a Scale | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 |
|---|---|---|---|---|
| Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12 | -1.5 ± 4.3 | -2.5 ± 6.5 | -3.7 ± 5.5 | -5.6 ± 8.5 |
Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 63 months). SAEs and Other AEs were assessed from first dose to 30 days after last dose of study therapy (assessed for an average of 11 months up to approximately 24 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/60 (0%) | 6/59 (10.2%) | 33/59 (55.9%) |
| 3 mg BMS-986165 | 0/86 (0%) | 11/84 (13.1%) | 55/84 (65.5%) |
| 6 mg BMS-986165 | 0/84 (0%) | 5/83 (6%) | 55/83 (66.3%) |
| 12 mg BMS-986165 | 0/9 (0%) | 2/9 (22.2%) | 7/9 (77.8%) |
| 6 mg BMS-986165 - Open Label | 0/161 (0%) | 15/161 (9.3%) | 86/161 (53.4%) |
| 12 mg BMS-986165 - Open Label | 0/6 (0%) | 1/6 (16.7%) | 3/6 (50%) |
| Event | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 | 6 mg BMS-986165 - Open Label | 12 mg BMS-986165 - Open Label |
|---|---|---|---|---|---|---|
| Breast abscessInfections and infestations | 0/59 | 0/84 | 0/83 | 0/9 | 0/161 | 1/6 |
| Infectious pleural effusionInfections and infestations | 0/59 | 0/84 | 0/83 | 0/9 | 0/161 | 1/6 |
| MediastinitisInfections and infestations | 0/59 | 0/84 | 0/83 | 0/9 | 0/161 | 1/6 |
| Crohn's diseaseGastrointestinal disorders | 3/59 | 5/84 | 2/83 | 1/9 | 6/161 | 0/6 |
| Hepatic cytolysisHepatobiliary disorders | 0/59 | 0/84 | 0/83 | 1/9 | 0/161 | 0/6 |
| SubileusGastrointestinal disorders | 1/59 | 0/84 | 0/83 | 0/9 | 0/161 | 0/6 |
| Abdominal abscessInfections and infestations | 1/59 | 0/84 | 0/83 | 0/9 | 0/161 | 0/6 |
| Anal abscessInfections and infestations | 1/59 | 0/84 | 0/83 | 0/9 | 0/161 | 0/6 |
| Lung abscessInfections and infestations | 1/59 | 0/84 | 0/83 | 0/9 | 0/161 | 0/6 |
| DepressionPsychiatric disorders | 1/59 | 0/84 | 0/83 | 0/9 | 0/161 | 0/6 |
| Event | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 | 6 mg BMS-986165 - Open Label | 12 mg BMS-986165 - Open Label |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/59 | 9/84 | 5/83 | 3/9 | 11/161 | 1/6 |
| Ventricular extrasystolesCardiac disorders | 1/59 | 0/84 | 0/83 | 0/9 | 0/161 | 1/6 |
| COVID-19Infections and infestations | 6/59 | 5/84 | 11/83 | 0/9 | 22/161 | 1/6 |
| NasopharyngitisInfections and infestations | 3/59 | 6/84 | 5/83 | 0/9 | 12/161 | 1/6 |
| Rib fractureInjury, poisoning and procedural complications | 0/59 | 0/84 | 0/83 | 0/9 | 0/161 | 1/6 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 0/59 | 0/84 | 0/83 | 0/9 | 0/161 | 1/6 |
| Traumatic haemothoraxInjury, poisoning and procedural complications | 0/59 | 0/84 | 0/83 | 0/9 | 0/161 | 1/6 |
| Breast haematomaReproductive system and breast disorders | 0/59 | 0/84 | 0/83 | 0/9 | 0/161 | 1/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/59 | 3/84 | 3/83 | 0/9 | 1/161 | 1/6 |
| Crohn's diseaseGastrointestinal disorders | 9/59 | 10/84 | 10/83 | 1/9 | 17/161 | 0/6 |
| Age, Continuous(Years) | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 | Total |
|---|---|---|---|---|---|
| Mean | 39.1 ± 16.7 | 39.5 ± 15.2 | 37.9 ± 14.6 | 37.4 ± 13.7 | 38.8 ± 15.3 |
| Sex: Female, Male(Participants) | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 | Total |
|---|---|---|---|---|---|
| Female | 22 | 38 | 34 | 3 | 97 |
| Male | 38 | 48 | 50 | 6 | 142 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 7 | 2 | 0 | 11 |
| Not Hispanic or Latino | 58 | 78 | 80 | 9 | 225 |
| Unknown or Not Reported | 0 | 1 | 2 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Placebo | 3 mg BMS-986165 | 6 mg BMS-986165 | 12 mg BMS-986165 | Total |
|---|---|---|---|---|---|
| Asian | 11 | 13 | 12 | 1 | 37 |
| Black or African American | 1 | 1 | 3 | 0 | 5 |
| White | 48 | 70 | 68 | 8 | 194 |
| Other | 0 | 2 | 0 | 0 | 2 |
| Not Reported | 0 | 0 | 1 | 0 | 1 |
Showing the first 100 of 259 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Dec 2022, 52 months.
Results were first posted in Jul 2024, 1 year 6 months after primary completion. A results delay was requested in Sep 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib